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Abstract
Background: TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) selectively induces apoptosis in various
cancer cells including myeloma (MM) cells. However, the susceptibility of MM cells to TRAIL is largely low in most of MM
cells by yet largely unknown mechanisms. Because TNF-a converting enzyme (TACE) can cleave some TNF receptor family
members, in the present study we explored the roles of proteolytic modulation by TACE in TRAIL receptor expression and
TRAIL-mediated cytotoxicity in MM cells.
Methodology/Principal Findings: MM cells preferentially expressed death receptor 4 (DR4) but not DR5 on their surface
along with TACE. Conditioned media from RPMI8226 and U266 cells contained a soluble form of DR4. The DR4 levels in
these conditioned media were reduced by TACE inhibition by the TACE inhibitor TAPI-0 as well as TACE siRNA. Conversely,
the TACE inhibition restored surface levels of DR4 but not DR5 in these cells without affecting DR4 mRNA levels. The TACE
inhibition was able to restore cell surface DR4 expression in MM cells even in the presence of bone marrow stromal cells or
osteoclasts, and enhanced the cytotoxic effects of recombinant TRAIL and an agonistic antibody against DR4 on MM cells.
Conclusions/Significance: These results demonstrate that MM cells post-translationally down-modulate the cell surface
expression of DR4 through ectodomain shedding by endogenous TACE, and that TACE inhibition is able to restore cell
surface DR4 levels and the susceptibility of MM cells to TRAIL or an agonistic antibody against DR4. Thus, TACE may protect
MM cells from TRAIL-mediated death through down-modulation of cell-surface DR4. It can be envisaged that TACE
inhibition augments clinical efficacy of TRAIL-based immunotherapy against MM, which eventually becomes resistant to the
present therapeutic modalities.
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Introduction
Multiple myeloma (MM) remains essentially incurable for the
vast majority of patients by conventional anti-tumor therapies,
which has led to increased interest in clinical application of various
forms of immune therapies. One such approach is the application
of TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL)
or TRAIL agonistic antibodies [1–4]. Because TRAIL is not
cytotoxic to normal tissues unlike Fas ligand and TNF-a, TRAIL-
mediated immunotherapy is tumor-specific, and regarded as an
attractive maneuver against various cancers including MM [5,6,7].
However, the susceptibility of MM cells to TRAIL has been
demonstrated to be largely low in most of MM cells, which limits
clinical applications of TRAIL-mediated immunotherapy. There-
fore, the development of novel therapeutic strategies to vitalize
TRAIL-induced apoptotic signaling in MM cells remains an
important clinical issue.
TRAIL binds to 2 different proapoptotic receptors, death
receptor 4 (DR4) and DR5. TRAIL and its receptors belong to
TNF-like ligand/receptor family members. TNF-a converting
enzyme (TACE) is known as a sheddase for TNF-like ligands/
receptors to modulate the biological activities of some of these
family members such as TNF-a [8,9]. Enforced expression of
tissue inhibitor of metalloproteinases-3 (TIMP-3), an endogenous
inhibitor for TACE, has been reported to up-modulate surface
levels of some TNF receptor family members including DR4 and
Fas in metastatic melanoma cell lines [10]. However, the role of
TACE in surface expression of TNF-like ligand/receptor family
members and the inhibition of TACE activity in TRAIL-mediated
cytotoxicity against MM cells has not been studied. In the present
study, we therefore investigated the role for TACE in TRAIL and
its receptor editing on MM cells as well as the effect of TACE
inhibition on TRAIL-triggered cytotoxicity in MM cells. We
demonstrate herein that MM cells post-translationally down-
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through ectodomain shedding by endogenous TACE, and that
TACE inhibition is able to restore cell surface DR4 expression and
the susceptibility of MM cells to TRAIL or an agonistic antibody
against DR4.
Results
Most hematopoietic malignant cells expresses TACE but
represses TIMP-3
Surface levels of some TNF receptor family members have been
suggested to be affected by enforced expression of TIMP-3 in
metastatic melanoma cell lines [10]. However, the expression of
TACE and its endogenous inhibitor, TIMP-3, has not been
precisely studied in malignant hematopoietic cells. Therefore, we
first investigated the expression of TACE and TIMP-3 in various
types of malignant cells. TACE mRNA was constitutively
expressed in all cell lines tested including RPMI8226, U266,
INA-6, MM.1S AND KMS12 MM cell lines, HL-60, U937
leukemic cell lines, and EBV-transformed B cell lines as well as
normal PBMCs (Figure 1). However, these MM cell lines and most
of leukemic cells showed only marginal expression of TIMP-3
mRNA, while the B cell lines and normal PBMCs constitutively
expressed TIMP-3. These results suggest that TACE activity is
enhanced along with repression of TIMP-3 expression in most of
hematological malignant cells including MM and leukemic cells.
Cell surface DR4 levels are down-modulated by TACE in
MM cells
In order to clarify the role of TACE, we next determined
whether TACE affects the surface levels of TNF-like ligand/
receptor family members on MM cells. Both RPMI8226 and
U266 cells constitutively expressed DR4 and Fas on their surface
as determined by flow cytometry (Figure 2A). DR5 was expressed
in RPMI8226 cells but marginally in U266. To clarify the role of
TACE in editing of these molecules on MM cells, we examined
their surface levels upon TACE inhibition by the TACE inhibitor
TAPI-0. After incubating with TAPI-0 for 24 hours the surface
levels of DR4 were enhanced on both RPMI8226 and U266 cells,
while DR5 and Fas showed no appreciable change (Figure 2A).
Up-modulation of surface DR4 levels by the TAPI-0 treatment
were also obtained in other MM cell lines, MM.1S, KMS12,
TSPC-1, UTMC-2 and OPC, primary MM cells, leukemic cell
lines, HL-60, and MD-MB-231 breast cancer cell line (Figure 2B).
These results suggest that surface DR4 expression is down-
modulated by endogenous TACE in malignant tumors including
MM.
TACE mediates the ectodomain shedding of DR4 in MM
cells
To clarify ectodomain shedding of DR4 in MM cells by TACE,
we next examined the effects of TACE inhibition on the levels of
DR4 in both cell lysates and conditioned media by Western
blotting using antibody against DR4 ectodomain. Conditioned
media from RPMI8226 and U266 cells contained an immunore-
active DR4 protein with a molecular size smaller than that
observed in their cell lysates. Interestingly, the treatment with
TAPI-0 reduced DR4 levels in culture supernatants of these MM
cells, while increasing them in their cell lysates (Figure 3A).
However, the TAPI-0 treatment showed no significant effects on
DR4 mRNA expression in RPMI8226 and U266 cells at 3, 6 and
12 hours (Figure 3B). We further examined the DR4 mRNA levels
in different MM cell lines, including RPMI8226, U266, OPC,
TSPC-1, KMS12-BM, and MM.1S cells, at 6, 12 and 48 hours in
the presence or absence of TAPI-0. The DR4 mRNA levels
showed no appreciable change in the presence of TAPI-0 in these
cells at 48 hours as well as 6 and 12 hours (Figure S1), although
surface protein levels of DR4 were up-modulated by the TAPI-0
treatment in these cells (Figures 2A and 2B). From these results,
the up-modulation of surface DR4 levels by TAPI-0 is suggested to
be largely due to the suppression of its ectodomain shedding. To
further confirm the role of TACE in ectodomain shedding of DR4,
we examined the effects of TACE siRNA on surface expression of
DR4. Treatment with TACE siRNA suppressed TACE expression
at a protein level in RPMI8226 and U266 cells in parallel with
resumption of DR4 levels in their cell lysates (Figure 3C). These
observations are consistent with the notion that surface DR4 levels
are post-translationally down-modulated by endogenous TACE in
MM cells.
TACE inhibition enhances the susceptibility of MM cells
to TRAIL or an agonistic antibody against DR4
We next investigated whether restoration of cell-surface DR4
levels by TACE inhibition is able to enhance the cytotoxic effects
of TRAIL or an agonistic antibody against DR4 on MM cells.
Treatment with recombinant TRAIL reduced the viability of
MM.1S and RPMI8226 cells (Figure 4A). Combination with the
TACE inhibitor TAPI-0 further reduced the viability of these cells,
although TAPI-0 alone did not show significant effects. Addition
of rh osteoprotegerin, an inhibitory decoy receptor for TRAIL,
mostly abolished the cytotoxic effects of recombinant TRAIL on
RPMI8226 cells in both the absence and presence of TAPI-0
(Figure 4A), which indicates that the TAPI-0’s effects are TRAIL-
dependent. Besides recombinant TRAIL, R1-B12, an anti-DR4
agonistic antibody, induced cell death in DR4-expressing
RPMI8226 and U266 cells (Figure 4B). However, the anti-DR5
Figure 1. The expression of TACE and TIMP-3 in various types
of hematopietic malignant cells. TACE and TIMP-3 mRNA
expression was analysed by RT-PCR in MM, B-lymphoid and leukemic
cell lines as indicated as well as normal PBMCs. Human GAPDH was
used as a housekeeping gene for quantity normalization.
doi:10.1371/journal.pone.0031594.g001
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cells but not in U266 cells at relatively higher concentrations,
which is consistent with surface expression levels of DR5 on these
cells. TACE inhibition by TAPI-0 treatment enhanced the
cytotoxic effects of R1-B12 on RPMI8226, UTMC-2, MM.1S
and OPC cells (Figure 4C). Although MM.1S cells appeared to be
susceptible to TRAIL in our experimental condition, their
susceptibility to TRAIL has been differently reported [11–13].
To substantiate the laboratory observations, we examined the
cytotoxic effects of R1-B12 on bone marrow cells from 2 patients
with MM in the presence or absence of the TACE inhibitor TAPI-
0. MM cell fractions were gated according to their expression of
CD138, a specific marker for MM cells, as marked in the
histograms in flow cytometry (Figure 4D). Per cent distribution of
CD138-positive MM cells in whole bone marrow cells was
reduced by the treatment with R1-B12 at 1.0 mg/ml in patient 1
and at 0.5 mg/ml in patient 2. The combinatory treatment with
TAPI-0 further reduced the % distribution of CD138
+ MM cells
(4.7% vs. 2.9% in patient 1 and 12.4% vs. 7.9% in patient 2,
respectively). These results suggest that TACE inhibition is able to
sensitize primary MM cells to TRAIL-mediated cell death,
although higher doses of R1-B12 were required to induce cell
death in primary MM cells compared to MM cell lines.
Although U266 cells express DR4 on their surface (Figure 2A),
they appear to be rather resistant to agonistic R1-B12 compared to
RPMI8226 cells (Figure 4B). Treatment with TAPI-0 slightly
potentiated the cytotoxic effects of R1-B12 at 10 nM but not at
100 nM on U266 cells (Figure 4C). Thus, U266 cells appear to
remain resistant to R1-B12 even after up-modulation of DR4 with
the TACE inhibition. Besides the surface levels of DR, the DR-
mediated pro-apoptotic signaling is intracellularly regulated. C-
FLICE-like interleukin protein (c-FLIP) is a predominant negative
regulator for the DR-mediated intracellular pro-apoptotic signal-
ing, which inhibits caspase8 activation. U266 cells were found to
constitutively over-express c-FLIP; and the knockdown of c-FLIP
by its siRNA significantly restored the cytotoxic effects of R1-B12
on U266 cells (manuscript in preparation). Therefore, inhibition of
the DR-mediated pro-apoptotic signaling pathway by c-FLIP is
suggested to largely contribute to the resistance of U266 cells to
R1-B12. Both the up-modulation of surface DR4 by TACE
inhibition and the potentiation of the DR-mediated pro-apoptotic
signaling are suggested to be required for full restoration of the
susceptibility of MM cells to TRAIL-mediated immunotherapy.
The osteosarcoma cell line MG63 was found to express no
appreciable DR4 protein on their surface but weakly DR4 mRNA.
In this cell line, treatment with TAPI-0 showed no appreciable
change in the surface levels of DR4 and did not induce the
cytotoxic effects of R1-B12 (data not shown). PBMCs from normal
subjects and CD138-negative normal hematopoietic cells in the
bone marrow also showed no detectable levels of surface DR4 in
flow cytometry. The treatment with TAPI-0 induced neither
surface DR4 nor cell death by R1-B12 in these normal cells.
Therefore, the TACE inhibition is suggested to be able to
effectively enhance surface DR4 levels and R1-B12-mediated cell
death in malignant cells expressing at detectable levels of surface
DR4. Collectively, the present strategy with R1-B12 in combina-
tion with TACE inhibition can work well for malignant cells
exhibiting detectable levels of DR4 without attenuation of the DR-
mediated intracellular pro-apoptotic signaling.
Because bone marrow stromal cells or osteoclasts confer
resistance against apoptosis in MM cells, we next asked whether
the TACE inhibition is able to enhance the DR4-mediated
cytotoxic effects on MM cells in the presence of bone marrow
stromal cells or osteoclasts. Surface DR4 levels seemed marginally
or only slightly affected in MM cells including RPMI8226, U266,
Figure 3. TACE is responsible for ectodomain shedding of DR4.
A. Cell lysates and culture supernatants were harvested after culturing
RPMI8226 and U266 cells for 48 hours in the absence or presence of
TAPI-0 at 10 mM. DR4 immunoreactivity was analyzed by immunoblot-
ing with an antibody against an DR4 extracellular domain. B. RPMI8226
and U266 cells were cultured for different hours as indicated in the
absence or presence of TAPI-0 at 10 mM. DR4 mRNA expression was
analysed by RT-PCR in RPMI8226 and U266 cells. GAPDH was used for
quantity normalisation. C. RPMI8226 and U266 cells seeded in 24-well
plates were transfected with TACE or control scrambled siRNA. After
culturing for 48 hours, cell lysates were harvested. DR4 immunoreac-
tivity was analysed by immunobloting. b-actin was used as a loading
control.
doi:10.1371/journal.pone.0031594.g003
Figure 2. Up-modulation of cell surface DR4 levels by TACE inhibition. A. RPMI8226 and U266 cells were cultured for 24 hours in the
absence (dotted lines) or presence (solid lines) of TAPI-0, a TACE inhibitor, at 10 mM. Surface expression of DR4, DR5 and Fas was analyzed by flow
cytometry. B. Surface expression of DR4 was analyzed by flow cytometry in various types of cell lines as indicated as well as primary MM cells after
culturing for 24 hours in the absence (dotted lines) or presence (solid lines) of TAPI-0 at 10 mM. Background staining with normal IgG is shown in
gray.
doi:10.1371/journal.pone.0031594.g002
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stromal cells or osteoclasts (Figure 5A). Similar to MM cells
cultured alone, TAPI-0 treatment increased surface DR4 levels in
MM cells even in the presence of bone marrow stromal cells
(Figure 5B). The anti-DR4 agonistic antibody R1-B12 was able to
induce cell death in MM cells in the presence of bone marrow
stromal cells (Figure 5C), although bone marrow stromal cells are
known to secrete a large amount of osteoprotegerin, a TRAIL
inhibitor [14,15]; TACE inhibition by TAPI-0 further enhanced
the DR4-mediated cell death with the antibody (Figure 5C).
Therefore, these results collectively suggest that restoration of DR4
by TACE inhibition enhances the susceptibility of MM cells to
DR4-mediated cell death.
The effects of our strategy on normal hematopoietic cells is an
important issue. To address this, we conducted hematopoietic
progenitor assays upon the treatment using R1-B12 with or without
TAPI-0. Addition of R1-B12 or R1-B12 plus TAPI-0 showed no
effects on the formation of CFU-GM and BFU-E from CD138-
negative normal bone marrow hematopoietic cells (Figure 5D).
Moreover, we examined the cytotoxic effects of our strategy on
normal bone marrow hematopoietic cells. The treatment with R1-
B12 or TAPI-0 alone, or both in combination showed no
appreciable change in the induction of apoptotic nor propidium
iodine (PI)-positive dead cells in CD138-negative normal bone
marrow hematopoietic cells isolated from a patient with MM
(Figure 5E). Therefore, our strategy appears not to sensitize normal
hematopoietic cells to TRAIL-mediated cell death. Furthermore,
CD34
+ hematopoietic progenitor cells purified from human cord
blood, adult peripheral blood or adult bone marrow have been
demonstrated not to express detectable levels of surface TRAIL
receptors and be resistant to TRAIL [16]. More recently, Mizrahi
K, et al. reported that TRAIL does not trigger apoptosis in
hematopoietic progenitors and rather enrich myeloid progenitors
[17]. Therefore, our strategy appears not to sensitize normal
hematopoietic cells to TRAIL-mediated cell death.
Discussion
Cytokine and growth factor signaling is controlled by the
amount of relevant ligands as well as the expression levels of their
cognate receptors. TACE cleaves and releases various cell surface
proteins from the plasma membrane, including cytokines and
cytokine receptors [8,9,18–20]. The cleavage of cytokine receptors
results in loss of their ligand binding capacity and shedding of their
soluble forms as a decoy receptor to interrupt binding of their
ligands to them, thereby drastically disrupting the activity of
cytokines as well as signal transduction through cytokine receptors
[18]. The present study demonstrates that DR4 on the surface of
tumor cells with enhanced TACE activity is post-translationally
down-modulated through TACE-mediated shedding. TACE-
mediated shedding appears to be an important mechanism for
the reduction of surface DR4 levels on MM cells, which may blunt
TRAIL-mediated apoptosis by surrounding immune cells express-
ing TRAIL to protect MM cells. Up-modulation of surface DR4
levels by inhibiting TACE activity is able to restore the
susceptibility of MM cells to TRAIL.
Although bone marrow stromal cells and osteoclasts create a
microenvironment which confers resistance against apoptosis in MM
cells, TACE inhibition is able to restore cell surface DR4 expression
in MM cells even in the presence of bone marrow stromal cells or
osteoclasts and enhance the cytotoxic effects of an agonistic antibody
against DR4 on MM cells (Figures 5B and 5C). Because tumor
immunity is suppressed in MM, the efficacy of immunotherapies
utilizing host immune cells is largely limited in patients with MM
[21]. In addition, osteoprotegerin, an endogenous inhibitor for
TRAIL, is abundantly secreted by bone marrow stromal cells in the
bone marrow in which MM cells preferentially reside [15]. Because
an agonistic antibody against DR4 can act on MM cells without host
immune cells and in the presence of osteoprotegerin, the anti-DR4
agonistic antibody with TACE inhibitors may become a novel
immunotherapeutic approach against MM.
TNF-a is regarded as an important cytokine produced by MM
cells and surrounding cells in the bone marrow in MM [22]. TNF-
a is activated from inactive pro- TNF-a by TACE, and released
from a cell surface. It directly stimulates MM cell growth and
survival as well as creates pathological microenvironment with
enhanced ostesclastogenesis and angiogeneisis [23–25]. TNF-a
activates NF-kB in MM cells, which leads to enhance the
expression of c-FLIP, a potent inhibitor for caspase8 activation,
to attenuate the death receptor-mediated apoptotic pathway
[26,27]. Therefore, the suppression of TNF-a activation by
TACE inhibition may also help TRAIL-induced MM cell death.
Collectively, it can be envisaged that TACE inhibition
augments clinical efficacy of TRAIL-based immunotherapy
against MM which eventually becomes resistant to the present
therapeutic modalities. This novel therapeutic modality can also
be applied to other types of cancers exerting TACE activity.
However, malignant cell resistance to TRAIL is largely caused by
the down-regulation of TRAIL receptor expression and the
suppression of its downstream pro-apoptotic signaling. To resume
the sensitivity to TRAIL, the development of novel therapeutic
maneuvers is required to up-modulate surface TRAIL receptors
along with the implementation of stimulators of the DR-mediated
pro-apoptotic signaling. The combination of TACE inhibition
with activators for caspase8 such as histon deacetylase inhibitors,
lenalidomide or bortezomib may further improve the efficacy of
TRAIL-based immunotherapy. Overall clinical benefits of these
strategies will be determined in well-deigned clinical studies.
Materials and Methods
Reagents
The following reagents were purchased from the indicated
manufacturers: a TACE inhibitor, TAPI-0, from Calbiochem (Bad
Soden, Germany); recombinant human (rh) TRAIL, osteoprote-
gerin, mouse monoclonal antibodies against human TRAIL, DR4,
Figure 4. TACE inhibition enhances the cytotoxic effects of TRAIL and R1-B12 on MM cells. A. MM.1S and RPMI8226 cells were cultured in
quadruplicate in 24-well plates in the absence or presence of recombinant TRAIL at 20 ng/ml. TAPI-0 and rh osteoprotegerin (OPG) was added at
10 mM and 1 mg/ml, respectively, as indicated. B. RPMI8226 and U266 cells were cultured in quadruplicate in 24-well plates in the absence or
presence of the anti-DR4 agonistic antibody R1-B12 (%) or the anti-DR5 agonistic antibody R2-E11 (&) at the different concentrations as indicated. C.
RPMI8226, UTMC-2, MM.1S and OPC cells were cultured in quadruplicate in 24-well plates in the absence or presence of R1-B12. R1-B12 was added at
the different concentrations as indicated. TAPI-0 was added at 10 mM. After culturing for 24 hours, cell viability was determined by WST-8 assay. The
results are expressed as % change from controls without the treatment (mean +/2 SD). *, p,0.05. D. Per cent distribution of CD138-positive MM
cells. MM cell fractions were gated according to their expression of CD138, a specific marker for MM cells, as marked in the histograms. X and Y axis
represents a side scatter (SS) and forward scatter (FS), respectively. CD138 staining within the gated cells in the control (left lower) indicates that MM
cell fraction was correctly gated. Per cent distribution of CD138-positive MM cells was counted within whole bone marrow cells in in the histograms.
doi:10.1371/journal.pone.0031594.g004
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Fas, CD40 and CD27 from R&D Systems (Minneapolis, MN);
rabbit polyclonal anti-human DR4 (ectodomain-specific) antibody
from Santa Cruz Biotechnology (Santa Cruz, CA); fluorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG from BD
Pharmingen (San Diego, CA); rabbit anti-b-actin from Sigma (St.
Louis, MO); horseradish peroxidase (HRP)- anti-rabbit IgG from
Cell Signaling Technology (Beverly, MA); and goat F(ab9)2 anti-
human IgG Fc from Pierce (Rockford, IL). The human
monoclonal anti-DR4 agonistic antibody R1-B12 and the anti-
DR5 agonistic antibody R2-E11 were kindly provided by Kyowa
Hakko Kirin Co. Ltd. (Tokyo, Japan).
Cells and cultures
Human MM cell lines, RPMI8226 and U266, human myeloid
cell lines, HL-60, KG1a, KU812F and U937, human lymphoid
cell lines, ARH77 and IM-9, and human non-hematopoietic cell
lines, MD-MB231, MCF7 and Colo205, were obtained from
American Type Culture Collection (ATCC) (Rockville, MD). The
MM cell line INA6, MM.1S, UTMC-2 and KMS12-BM was
kindly provided by Dr. Renate Burger (University of Kiel, Kiel,
Germany), Dr. Steven Rosen (Northwestern University, Chicago,
IL), Dr. Alan Solomon (University of Tennessee, TN) and Dr.
Otsuki (Kawasaki Medical School, Okayama, Japan), respectively.
TSPC-1 and OPC MM cell lines were established in our
laboratory [28]. Bone marrow mononuclear cells were isolated
by Ficoll-Hypaque density gradient centrifugation (Pharmacia
LKB Biotechnology, Uppsala, Sweden) from heparinized bone
marrow blood drawn from patients with MM. MM cells were
further purified from bone marrow mononuclear cells with
positive selection using CD138 (Syndecan-1) microbeads and
Miltenyi magnetic cell sorting system (Miltenyi Biotec, Auburn,
CA) according to the manufacture’s instruction. The purity of the
MM cells was greater than 95%. Primary stromal cells derived
from fresh BM aspirates were isolated and cultured as we
previously described [28,29]. These cells are a homogeneous
population of spindle-shaped cells expressing CD44, CD73, CD90
and CD105, but neither CD45 nor factor VIII. OCs were
generated from peripheral blood mononuclear cells (PBMCs) as
previously reported [15]. Cells were cultured in aMEM supple-
mented with 10% fetal bovine serum (FBS), 2 mM of L-glutamine
(Sigma), 100 U/ml of penicillin G and 100 mg/ml of streptomy-
cin (Sigma). All procedures involving human specimens were
performed with written informed consent according to the
Declaration of Helsinki and using a protocol approved by the
Institutional Review Board for human protection.
Flow cytometry
Cell preparation and staining for flow cytometry were
performed as described previously [29]. Approximately 10
6 cells
were incubated in 100 ml PBS with 2% human c-globulin with
saturating concentrations of different FITC-conjugated monoclo-
nal antibodies on ice for 40 minutes and the washed. Samples
were analyzed by flow cytometry using EPICS-Profile (Coulter
Electronics, Hialeah, FL).
Western blot analysis
Cells were collected and lysed in lysis buffer (Cell Signaling)
supplemented with 1 mM phenylmethylsulfonyl fluoride and
protease inhibitor cocktail solution (Sigma). Cell lysates and
conditioned media were electrophoresed in 10% SDS-PAGE gel
and blotted onto polyvinylidene difluoride membranes (Millipore,
Bedford, MA). After blocking with 5% non-fat dry milk, the
membranes were incubated with primary antibodies overnight at
4uC, followed by washing and addition of a horseradish-
conjugated secondary antibody for one hour. The protein bands
were visualized with an Enhanced Chemiluminescence Plus
Western Blotting Detection System (Amersham Biosciences,
Piscataway, NJ).
RT-PCR
Total RNA was extracted from cells using TRIZOL reagent
(Gibco BRL, Rockville, MD). For reverse transcription-polymer-
ase chain reaction (RT-PCR), 2 mg total RNA was reverse-
transcribed with Superscript II (Gibco) in a 20-ml reaction solution.
One tenth of the RT-PCR products was used for subsequent PCR
analysis with 24–30 cycles of 95uC for 30 seconds, 58uC for
30 seconds, and 72uC for 30 seconds. The primers used were as
follows: Human TACE sense 59- ATTATTGGTGGTAGCA-
GATC-39 and antisense 59- GAGCCAACATAAGCTAATCC-
39. Human DR4 sense 59-TGGCACACAGCAATGGGAACA-
TAG-39 and antisense 59-GAAACACACCCTGTCCATG-
CACTT-39; and human TIMP-3 sense 59- GCAGATGAA-
GATGTACCGAG-39 and antisense 59- GTCTGTGGCAT-
TGATGATGC-39. Human GAPDH was used as a housekeeping
gene for quantity normalization (sense 59-AATCCCATCAC-
CATCTTCCA-39, antisense 59-TGGACTCCACGACGTACT-
CA-39).
Transfection
TACE siRNA (59-augaguuguaaccaggucagcuucc-39 and 59-
ggaagcugaccugguuacaacucau-39) and scrambled siRNA were
purchased from Invitrogen. Three mg of each siRNA was
transfected into cells seeded in 24-well plates by electroporation
using a Human Nucleofector Kit (Amaxa Biosystems, Cologne,
Germany).
Cell viability assay
rhTRAIL was added into cultures. In cytotoxic analyses with
R1-B12, R1-B12 was added into cultures followed by cross-linking
with goat F(ab9)2 anti-human IgG Fc. After culturing for 2 days,
viable cell numbers were counted by trypan blue dye exclusion
Figure 5. TACE inhibition enhances anti-MM effects of R1-B12 in the presence of bone marrow stromal cells. A. Surface DR4 levels on
MM cells in cocultures with bone marrow stromal cells or osteoclasts. MM cell lines as indicated were cultured alone (dotted line) or cocultured (solid
line) for 2 days with bone marrow stromal cells or osteoclasts (OCs). B. The effects of TAPI-0 on surface DR4 levels on MM cells in the cocultures. MM
cell lines as indicated were cultured alone (solid line) or cocultured (dotted line) with bone marrow stromal cells or osteoclasts (OCs). TAPI-0 was
added at 10 mM into the cocultures as indicated. After culturing for 2 days, MM cells were harvested, and surface expression of DR4 was analyzed by
flow cytometry. C. RPMI8226 and OPC cells were cocultured with bone marrow stromal cells. The anti-DR4 agonistic antibody R1-B12 at the different
concentrations and TAPI-0 at 10 mM were added as indicated. After culturing for 2 days, the viability of was RPMI8226 cells analysed by WST-8 assay.
Data are expressed as the change in viable cell numbers relative to a control without any agents (mean +/2 SD). *, p,0.05. D. Colony forming cell
assays. CD138-negative bone marrow cells were cultured in the absence or presence of R1-B12 or R1-B12 plus TAPI-0 for 14 days, and BFU-E and CFU-
GM were counted. E. The effects of R1-B12 plus TAPI-0 on normal hematopoietic cells. CD138-negative normal hematopoietic cells were isolated from
the bone marrow sample from a patient with MM, and treated for 2 days with R1-B12 or TAPI-0 alone, or both in combination. The cells were then
subject to annexin V-FITC and PI dual staining.
doi:10.1371/journal.pone.0031594.g005
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determined by Cell Counting Kit-8 assay (DOJINDO, Kuma-
moto, Japan) according to the manufacture’s instructions. Briefly,
cells were seeded in 96-well plate and incubated with 2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulphophenyl)-
2H-tetrazolium monosodium salt (WST-8) for 1–4 hours. The
absorbance of each well was measured at 450 nm with a microtiter
plate reader (Model 450 micro plate reader; Bio-Rad Laborato-
ries, Hercules, CA). Apoptosis and cell death were evaluated by
staining cells with an annexin V-FITC and PI labeling kit
(MEBCYTO Apoptosis Kit; MBL,Nagano, Japan) according to
the manufacture’s instruction.
Colony forming cell assays
CD138-negative bone marrow cells from a patient with MM
were cultured in the absence or presence of R1-B12 or R1-B12
plus TAPI-0 for 14 days in semi-solid methylcellulose media
(MethoCult H4034 Optimum, Stem Cell Technologies, Vancou-
ver, BC, Canada) according to the manufacturer’s instruction.
Colonies representing the hematopoietic progenitor cells were
counted under a scanning microscope and scored as burst-forming
unit-erythroid (BFU-E) and colony-forming unit-granulocyte,
macrophage (CFU-GM).
Statistical analysis
Statistical significance was determined by one-way analysis of
variance (ANOVA) with Scheffe’s post hoc tests. The minimal
level of significance was p=0.05.
Supporting Information
Figure S1 DR4 mRNA expression. RPMI8226, U266, OPC,
TSPC-1, KMS12-BM, and MM.1S cells were cultured for 6, 12
and 48 hours in the presence or absence of TAPI-0 at 10 mMa s
indicated. DR4 mRNA expression was analysed by RT-PCR in
RPMI8226 and U266 cells. GAPDH was used for quantity
normalization.
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